Payment overview · 2025
General Payments
$2,244.87
79 reported records · 15 companies
Healthcare provider profile · identity verified
Qing Yeh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1104834324
Verified facts
What the public records show
CMS Open Payments records show Qing Yeh, M.D. received $2,244.87 in general payments during 2025 across 79 reported records.
Amgen Inc. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Nexletol, Rybelsus, Shingrix, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $627.06 | 27.9% | 16 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $345.18 | 15.4% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $302.77 | 13.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.65 | 9.2% | 9 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $198.40 | 8.8% | 10 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $165.32 | 7.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.30 | 6.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.60 | 3.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.08 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.55 | 1.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $22.50 | 1.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.56 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.50 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.16 | 0.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.24 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,244.87 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $381.39 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $348.61 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $345.18 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $198.40 | 10 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $165.32 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $126.12 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.87 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $80.12 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.29 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $53.84 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $43.43 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 31 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 83 |
| Vascepa | Icosapent Ethyl | 276 | 69 |
| Diclofenac Epolamine | Diclofenac Epolamine | 206 | 63 |
| Losartan Potassium | Losartan Potassium | 204 | 61 |
| Metformin Hcl | Metformin Hcl | 186 | 54 |
| Farxiga | Dapagliflozin Propanediol | 131 | 38 |
| Raloxifene Hcl | Raloxifene Hcl | 131 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 27 |
| Omeprazole | Omeprazole | 92 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 33 |
| Vemlidy | Tenofovir Alafenamide | 81 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 80 | 27 |
| Linzess | Linaclotide | 64 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 15 |
| Alendronate Sodium | Alendronate Sodium | 62 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 34 |
| Restasis | Cyclosporine | 61 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 23 |
| Mometasone Furoate | Mometasone Furoate | 59 | 21 |
| Bepotastine Besilate | Bepotastine Besilate | 57 | 25 |
| Donepezil Hcl | Donepezil Hcl | 57 | 18 |
| Kerendia | Finerenone | 57 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Montelukast Sodium | Montelukast Sodium | 51 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 12 |
| Finasteride | Finasteride | 48 | 16 |
| Atenolol | Atenolol | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 43 | 14 |
| Ammonium Lactate | Ammonium Lactate | 42 | 20 |
| Telmisartan | Telmisartan | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 11 |
| Allopurinol | Allopurinol | 36 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Nexium | Esomeprazole Magnesium | 34 | 11 |
| Zenpep | Lipase/Protease/Amylase | 34 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 19 |
| Simvastatin | Simvastatin | 31 | 13 |
| Januvia | Sitagliptin Phosphate | 30 | 11 |
| Dutasteride | Dutasteride | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 19 |
| Famotidine | Famotidine | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 20 |
| Azithromycin | Azithromycin | 25 | 21 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 25 | 13 |
| Meloxicam | Meloxicam | 25 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 15 |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Gabapentin | Gabapentin | 20 | 11 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Prolia | Denosumab | 18 | 14 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | 13 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Licart | Diclofenac Epolamine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,244.87 · 79 records | Amgen Inc. | AIRSUPRA, AREXVY, BREZTRI, CREON, EVENITY, FASENRA, Fluad, Flucelvax, KRYSTEXXA, Korlym, Linzess, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, ZENPEP, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error